Approved Study Database
| Ref. No. | Scientific Title | Principal investigator |
|---|---|---|
| 2009.293 | A cross-sectional study of the prevalence of tinea pedis and onychomycosis in Hong Kong | Prof Wong Tze Wai |
| 2011.280 | Evaluation of Skin pruritus among patients with recovery from burn injury | Ms. Wong Tze Wing |
| 2017.509 | Myositis specific autoantibodies and their clinical association in idiopathic inflammatory myopathies in Hong Kong | Dr. WONG Victor Tak Lung |
| 2017.703 | Automated fibrosis staging in nonalcoholic fatty liver disease: A retrospective cohort study using the dual-photon microscopy technology |
Dr. WONG Vincent 黃煒燊 |
| 2015.495 | Novel magnetic resonance imaging patients with chronic liver diseases – a cross-sectional study with histological correlation |
Dr. WONG Vincent 黃煒燊 |
| 2017.310 | Predicting fibrosis progression in patients with non-alcoholic fatty liver disease using clinical, genetic and baseline histological assessments: A prospective cohort study |
Dr. WONG Vincent 黃煒燊 |
| 2015.452 | Prognostication of nonalcoholic fatty liver disease and chronic hepatitis B with controlled attenuation parameter and liver stiffness measurement by Fibroscan – A prospective cohort study |
Dr. WONG Vincent 黃煒燊 |
| 2014.691 | Prediction of hepatocellular carcinoma with serum methylated RASSF1A in patients with chronic hepatitis B on antiviral therapy: A longitudinal study | Dr Wong Vincent |
| 2015.505 | Incidence of non-alcoholic fatty liver disease and advanced fibrosis in patients with type 2 diabetes: A prospective cohort study using paired controlled attenuation parameter and liver stiffness measurements |
Dr. WONG Vincent 黃煒燊 |
| 2013.678 | Brown adipose tissue and body fat distribution in non-alcoholic steatohepatitis: A clinicopathological study using fat-water magnetic resonance imaging | Dr Wong Vincent |
| 2013.677 | Consolidation of lifestyle modification program with mobile phone text messaging in patients with non-alcoholic fatty liver disease: A randomized controlled trial | Dr Wong Vincent |
| 2021.634 | Gut microbiome and metabolites in Non-alcoholic fatty liver diseases |
Prof. WONG Vincent 黃煒燊 |
| 2022.208 | Clinical and prognostic significance of intrahepatic fibroblast activation protein expression in patients with non-alcoholic fatty liver disease |
Dr. WONG Vincent 黃煒燊 |
| 2021.606 | Viral Load and Hepatocellular Carcinoma Risk in Chronic Hepatitis B: Time to Consider Extended Treatment Indications |
Dr. WONG Vincent 黃煒燊 |
| 2023.471 | Validation and refinement of serum multi-OMIC signature for identifying liver fibrosis and metabolic dysfunction-associated steatohepatitis in the Asian population |
Dr. WONG Vincent 黃煒燊 |
| 2022.622 | A Phase IIb/III Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of Cotadutide in Participants with Non-cirrhotic Non-alcoholic Steatohepatitis with Fibrosis |
Prof. WONG Vincent 黃煒燊 |
| 2022.255 | Prognostic implication of baseline and changes in liver stiffness measurement and the FibroScan-aspartate aminotransferase (FAST), Agile 3+ and Agile 4 scores in patients with non-alcoholic fatty liver disease: A retrospective cohort study |
Dr. WONG Vincent 黃煒燊 |
| 2023.436 | Monitoring changes in hepatic steatosis during a lifestyle intervention programme in patients with non-alcoholic fatty liver disease using the novel continuous controlled attenuation parameter versus MRI proton density fat fraction |
Dr. WONG Vincent 黃煒燊 |
| 2018.230 | Incidence of liver-related events among patients with psychiatric illness: A retrospective cohort study |
Dr. WONG Vincent 黃煒燊 |
| 2018.236 | Prevalence and severity of chronic liver diseases among patients with psychiatric illness: A cross-sectional study using transient elastography |
Dr. WONG Vincent 黃煒燊 |
| 2020.304 | SGLT2 inhibitors and liver-related outcomes in patients with type 2 diabetes mellitus: A territory-wide retrospective cohort study |
Dr. WONG Vincent 黃煒燊 |
| 2019.136 | Characterization of biology of nonalcoholic fatty liver disease by single-cell RNA sequencing |
Dr. WONG Vincent 黃煒燊 |
| 2019.139 | Identification of fatty liver with advanced fibrosis in patients with type 2 diabetes using simple fibrosis scores and electronic reminder messages: A randomized controlled trial |
Dr. WONG Vincent 黃煒燊 |
| 2025.071 | Prevalence and clinical significance of detectable blood phosphatidylethanol in patients with metabolic dysfunction-associated steatotic liver disease and chronic hepatitis B |
Dr. WONG Vincent Vincent Wong |
| 2017.422 | A Phase 4, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study Evaluating the Effect of Obeticholic Acid on Clinical Outcomes in Subjects with Primary Biliary Cholangitis |
Prof. WONG Vincent W.S. 黃偉燊 |
| 2003.338 | A Study on Nonalcoholic Steatohepatitis (NASH) in Hong Kong | Prof. WONG Vincent W.S. |
| 2014.586 | CENTAUR: Efficacy and Safety Study of Cenicriviroc for the Treatment of Nonalcoholic Steatohepatitis (NASH) in Adult Subjects with Liver Fibrosis | Prof. WONG Vincent Wai Sun |
| 2017.001 | Optimizing varices screening in cirrhotic patients with well-controlled chronic viral hepatitis: A prospective cohort study with transient elastography and multiparametric magnetic resonance imaging |
Dr. WONG Vincent Wai Sun 黃煒燊 |
| 2017.258 | AURORA: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects with Nonalcoholic Steatohepatitis |
Prof. WONG Vincent Wai Sun 黃煒燊 |
| 2017.257 | Open-label Rollover Study of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects with Nonalcoholic Steatohepatitis (NASH) |
Prof. WONG Vincent Wai Sun 黃煒燊 |
| 2016.698 | Non-invasive diagnosis and prognosis of nonalcoholic steatohepatitis and liver fibrosis: A clinicopathological study of metabolite, lipid, and protein biomarkers |
Dr. WONG Vincent Wai Sun 黃煒燊 |
| 2017.511 | Biomarkers study on biological samples from NAFLD and NASH patients from the biobank at the Chinese University of Hong Kong |
Dr. WONG Vincent Wai Sun 黃煒燊 |
| 2016.606 | A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety, Tolerability, and Efficacy of GS-9674 in Subjects with Nonalcoholic Steatohepatitis (NASH) |
Prof. WONG Vincent Wai Sun 黃煒燊 |
| 2017.166 | A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Selonsertib in Subjects with Compensated Cirrhosis due to Nonalcoholic Steatohepatitis (NASH) |
Prof. WONG Vincent Wai Sun 黃煒燊 |
| 2017.611 | A 12-week randomized, patient and investigator blinded, placebo-controlled, parallel group study to investigate the efficacy of LIK066 in obese patients with non-alcoholic steatohepatitis (NASH) |
Prof. WONG Vincent Wai Sun 黃煒燊 |
| 2006.439 | Collection of Blood and Liver Biopsy Samples for Liver Fibrosis Study | Dr. WONG Vincent Wai Sun |
| 2024.451 | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with non-cirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis |
Prof. WONG Vincent Wai Sun Wai Sun Vincent Wong |
| 2024.292 | A Phase 3 Study to Evaluate the Efficacy and Safety of Pegozafermin in Subjects with Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Fibrosis |
Prof. WONG Vincent Wai Sun 黃煒燊 |
| 2024.440 | A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis |
Prof. WONG Vincent Wai Sun Wai Sun Vincent Wong |
| 2024.591 | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE II CLINICAL STUDY EVALUATING THE EFFICACY AND SAFETY OF DR10624 INJECTION IN SUBJECTS AT HIGH RISK OF LIVER FIBROSIS WITH METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE AND METABOLIC DYSFUNCTION AND ALCOHOL ASSOCIATED STEATOTIC LIVER DISEASE | Prof. WONG Vincent Wai Sun |
| 2024.371 | A Phase 3 Study to Evaluate the Efficacy and Safety of Pegozafermin in Subjects with Compensated Cirrhosis due to Metabolic Dysfunction-Associated Steatohepatitis (MASH) |
Prof. WONG Vincent Wai Sun Vincent Wai Sun Wong |
| 2024.124 | Assessing the safety of discontinuing non-selective beta-blockers in cirrhotic patients with managed primary aetiological factors according to Baveno VII consensus |
Professor Wong Vincent Wai Sun 黃煒燊 |
| 2020.602 | A Phase 2b Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of MK-3655 in Individuals With Pre-cirrhotic Nonalcoholic Steatohepatitis |
Prof. WONG Vincent Wai Sun 黃煒燊教授 |
| 2018.151 | A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Selonsertib, GS-0976, GS-9674, and Combinations in Subjects with Bridging (F3) Fibrosis or Compensated Cirrhosis (F4) due to Nonalcoholic Steatohepatitis (NASH) |
Prof. WONG Vincent Wai Sun 黃煒燊 |
| 2019.415 | A Phase 2b, Multicenter, Double-blind, Active Controlled, Randomized Study to Investigate the Efficacy and Safety of different combination regimens including JNJ-73763989 and/or JNJ-56136379 for the treatment of Chronic Hepatitis B Virus Infection | Prof. WONG Vincent Wai Sun |
| 2020.306 | Evaluation of Efficacy, Safety and Tolerability of NGM282 (Aldafermin) in a Phase 2b, Randomized, Double-blind, Placebo-controlled, Multi-center Study in Subjects with Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (ALPINE 4) |
Prof. WONG Vincent Wai Sun 黃煒燊 |
| 2018.301 | A Registry Study to Assess Patient Reported Outcomes (PRO’s) in Patients with Liver Diseases (CLD-PRO Global Registry Study) |
Prof. WONG Vincent Wai Sun 黃煒燊 |
| 2020.303 | A Phase 2, Randomized, Double-blind, Double-dummy, Placebo-controlled, Dose-ranging, Dose-finding, Parallel Group Study to Assess Efficacy and Safety of PF 06865571 (DGAT2i) Alone and When Coadministered with PF-05221304 (ACCi) in Adult Participants with Biopsy-confirmed Nonalcoholic Steatohepatitis and Fibrosis Stage 2 or 3 |
Prof. WONG Vincent Wai Sun 黃煒燊 |
| 2021.107 | Population prevalence and severity of nonalcoholic fatty liver disease in Hong Kong: A 2008-2010 and 2022-2024 comparison using MRI-PDFF and transient elastography |
Dr. WONG Vincent Wai Sun 黃煒燊 |
| 2023.182 | A Phase 2b, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of HTD1801 in Adult Subjects with Nonalcoholic Steatohepatitis (NASH) and Liver Fibrosis who Have Type 2 Diabetes or Pre-Diabetes (The CENTRICITY Study) | Prof. WONG Vincent Wai Sun |
Page 241 of 265.